Related Experiment Video
Updated: Jun 3, 2025
11:10
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
2.2K
Apocynin, a Selective NADPH Oxidase (Nox2) Inhibitor, Ameliorates Behavioural and Learning Deficits in the Fragile X
Yolanda de Diego-Otero1, Rajaa El Bekay2,3,4, Francisco García-Guirado2
1Cellular Biology, Physiology and Immunology Department, University of Córdoba, 14014 Córdoba, Spain.
Biomedicines
|January 8, 2025
Summary
Apocynin, an NADPH oxidase inhibitor, reduced hyperactivity and improved behavior and learning in male Fragile X mice. This suggests Apocynin may be a potential therapeutic option for Fragile X Syndrome.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Fragile X Syndrome (FXS) is a genetic disorder linked to intellectual disability, hyperactivity, social anxiety, and autism spectrum disorder.
- Hyperactivation of NADPH oxidase has been observed in the brain of male Fmr1-knockout (KO) mice, a model for FXS.
Purpose of the Study:
- To evaluate the efficacy of Apocynin, a NADPH oxidase inhibitor, in ameliorating FXS hallmarks in male Fmr1-KO mice.
- To investigate the impact of Apocynin on oxidative stress markers, behavior, and learning in the FXS mouse model.
Main Methods:
- Chronic oral administration of vehicle, 10 mg/kg/day, or 30 mg/kg/day of Apocynin to male Fmr1-KO mice.
- Assessment of free radicals, lipid and protein oxidation markers, and behavioral and learning paradigms.
- Analysis of phospho-ERK1 and P47-Phox protein levels in specific brain regions.
Main Results:
- Apocynin treatment led to a reduction in hyperactivity in male Fmr1-KO mice.
- The higher dose (30 mg/kg/day) improved behavior and learning, normalizing free radical production and oxidative stress markers.
- Reduced phospho-ERK1 and P47-Phox protein signals were observed in specific brain areas following Apocynin treatment.
Conclusions:
- Chronic Apocynin treatment demonstrates potential in mitigating key pathological features of Fragile X Syndrome in mice.
- Apocynin normalizes oxidative stress and improves cognitive and behavioral deficits, suggesting its therapeutic potential for FXS.
